Close Menu

NEW YORK – Enzo Biochem reported this week that it estimates its revenues for the quarter ending Oct. 31 will meet or exceed $27 million, representing sequential growth of at least 40 percent.

The company also said that Fabian Blank and Peter Clemens have resigned from the board of directors, effective immediately. Both board members were originally nominated by Enzo investor Harbert Discovery Fund. Separately, the company said Mary Tagliaferri has been appointed to the board, effective immediately.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.